Scientists at the Barshop Institute have demonstrated that orally administered eRapa can
prevent the development of Alzheimer’s pathologies in mice.
Utilizing mice genetically prone to develop Alzheimer’s disease, UTHSCSA scientists have shown orally administered eRapa™ is effective in preventing the cognitive deficits of memory loss and anxiety, along with preventing the accumulation of amyloid-beta and tau proteins in the brain which are both used as indicative, pathologic cerebral biomarkers for Alzheimer’s disease. UTHSCSA scientists have also shown eRapa administration increases intra-cerebral blood flow in brain regions of mice compromised by Alzheimer’s-related pathologies. We believe demonstration of eRapa-induced restoration of cerebral blood flow in our future clinical studies will lead to significant interest from potential commercial partners.
Journal of Cerebral Blood Flow & Metabolism (2013) 33, 1412–1421; published online 26 June 2013. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease.
Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options www.sciencedirect.com. Current Opinion in Pharmacology 2011, 11:378-394). Giuseppe Pignataro, et al.
Chronic inihibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 223 (2012) 102-113. A. Richardson, V. Galvan.
Mammalian Target of Rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer’s disease? Journal of Neuroscience Research 90:1105-1118 (2012). Cai, et al.